Sales and earnings by business segment

In 2011, we expect further increases in sales and earnings in each of our business segments. The table gives an overview.

Financial Targets by Business Segment


  Targets 2011 Fiscal year 2010
1 Net income attributable to Fresenius Medical Care AG & Co. KGaA
2 Sales
3 EBIT
Fresenius Medical Care
Sales US$12.8–13.0 bn US$12,053 m
Net income1 US$1,035 m–US$ 1,055 m US$979 m
Fresenius Kabi
Sales growth (organic) ~ 5% €3,672 m2
EBIT margin > 19% 20.1%
Fresenius Helios
Sales growth (organic) 3–5% €2,520 m2
EBIT €250 m–€260 m €235 m
Fresenius Vamed
Sales growth 5–10% €713 m2
EBIT growth 5–10% €41 m3
Fresenius Biotech
EBIT ~ -€30 m -€32 m

  Targets 2011 Fiscal year 2010
1 Net income attributable to Fresenius Medical Care AG & Co. KGaA
2 Sales
3 EBIT
Fresenius Medical Care
Sales US$12.8–13.0 bn US$12,053 m
Net income1 US$1,035 m–US$ 1,055 m US$979 m
Fresenius Kabi
Sales growth (organic) ~ 5% €3,672 m2
EBIT margin > 19% 20.1%
Fresenius Helios
Sales growth (organic) 3–5% €2,520 m2
EBIT €250 m–€260 m €235 m
Fresenius Vamed
Sales growth 5–10% €713 m2
EBIT growth 5–10% €41 m3
Fresenius Biotech
EBIT ~ -€30 m -€32 m

The number of dialysis patients worldwide should rise by about 6% again in 2011, leading to continued growth in demand for dialysis products and a higher number of treatments. In 2011, Fresenius Medical Care expects to achieve revenue of US$12.8 to US$13.0 billion. Net income is expected to be between US$1.035 million and US$1.055 million.

Fresenius Kabi expects its positive operating performance to continue in 2011. Due to the high base achieved by an exceptional growth in North America, growth rates will be moderate in 2011. However, the company projects organic sales growth of about 5%. High growth potential is expected again in the Asia-Pacific region and in Latin America. Based on this positive sales projection, further cost optimizations, especially in production, and an improved product mix, Fresenius Kabi again expects to increase earnings in 2011. Fresenius Kabi forecasts an EBIT margin of > 19%, again achieving an excellent margin level.

Fresenius Helios expects a continued good performance in the hospital operations business. The company forecasts an organic sales growth of 3% to 5% in 2011. EBIT is expected to increase to €250 million to €260 million.

Given its excellent order backlog of €801 million and longterm agreements in its service business, Fresenius Vamed has an excellent base for further growth. In 2011, Fresenius Vamed expects to achieve both sales and EBIT growth between 5% and 10%.

Fresenius Biotech is expected to further reduce its negative EBIT to about -€30 million.

Continue reading:
Financing

QUICKFINDER

History

Internal related Links

Tools